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1086-139 Comparison Between Successful and Unsuccessful 
Mitral Valve Repair of Ischemic Mitral Regurgitation: An 
Echocardiographic Follow-Up Study
Maiko Shiota, Jian Xin Qin, Patrick M. McCarthy, A. Marc Gillinov, John-Han Shin, 
Timothy Williams, Delos M. Cosgrove, James D. Thomas, Takahiro Shiota, Cleveland 
Clinic Foundation, Cleveland, OH
Ischemic mitral regurgitation (IMR) is commonly treated by ring annuloplasty, but it is
unclear what factors contribute to the success of annular reduction surgery. This study
aimed to investigate predictive echo factors for the success of mitral valve (MV) repair.
Methods: 437 patients underwent MV repair for IMR at Cleveland Clinic Foundation
between April 1990 and November 2002. 76 patients were excluded from this study due
to insufficient or inconsistent echo reports or clinical information. Pre-operative echo data
in the remaining 361 patients were analyzed, including ejection fraction (EF), left atrial
diameter (LAD), left ventricular end-diastolic diameter (LVDD) and end-systolic diameter
(LVSD). Severity of mitral regurgitation (MR) was graded on a scale of 0 to 4.
Results (Table): 298 patients (83%) had satisfactory outcomes with <2+ MR, while 63
(17%) had recurrent significant MR (>2+) during follow-up. There was no significant dif-
ference in age, sex, EF and follow up period between the 2 groups. The success group
was found to have a smaller LAD, LVDD, and LVSD pre-operatively than the recurrent MR
group. The most striking difference between the two groups was the severity of MR
before repair. 
Conclusion: LAD, LVDD, LVSD and especially MR severity in preoperative 2D echo were
larger or worse in the recurrent MR group as compared to the success one. Accordingly,
MV repair should be carefully selected in IMR patients with larger left atrium/left ventricle
and more severe MR.
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1107-135 Neoangiogenesis via Vascular Endothelial Growth 
Factor Expression Is Associated With an Osteoblast-
like Bone Formation in Calcified Rheumatic Heart 
Valves
Thomas B. Nealis, Stuart Stock, Khuram H. Siddiqi, Thenappan Thenappan, Thomas C. 
Sebo, Stephen W. Carmichael, James Frederiksen, Malayannan Subramanium, William 
D. Edwards, Thomas C. Spelsberg, Robert O. Bonow, Nalini M. Rajamannan, 
Northwestern University, Chicago, IL, Mayo Clinic, Rochester, MN
Intro: Rheumatic fever is the most common cause of valvular heart disease in developing
countries. Despite its high prevalence, the inflammatory-immune and fibrocalcific mecha-
nisms leading to progressive valvular dysfunction are not well characterized. We hypoth-
esized that calcification is associated with osteoblastic bone formation and angiogenesis.
Methods: To test this hypothesis we examined human rheumatic valves (RV) replaced at
surgery (n=23) and normal human valves (nl) (n=20). Micro computed tomography was
used to assess mineralization fronts to reconstruct the 2 dimensional and 3 dimensional
extent of mineralization. Hematoxylin and eosin, Masson trichrome stains were per-
formed. Immunohistochemistry was used to localize osteopontin protein, alpha actin,
CD34, Vascular Endothelial Growth Factor (VEGF), von willebrand factor (VWF), and
CD68 stains (human macrophage). Quantification of PCNA was performed by computer
analysis (Quantification of Proliferation Index Baccus, Inc, Lombard, IL). Results: H and
E, and Masson Trichrome stains confirmed the presence of mineralization in areas of
intense calcification of the calcified rheumatic heart valves as compared to normal
valves. Immunohistochemistry localized osteopontin to smooth muscle cells within the
microvessels within the valves. MicroCT demonstrated calcification with complex forma-
tions developing within the mineralized tissues. Immunohistochemistry markers including
VEGF and CD34 for angiogenesis were positive in areas of inflammation (CD68). In cells
staining for alpha-actin, PCNA index was positive in 5 of 22 cardiac valves in the alpha
actin staining cells (1.26+/-0.32 (nl) versus 37.64 (RV)). The amount of new vessels
present were positive in 19 of 22 valves (0 (nl) versus 21.55+/-22.08(RV)). These mark-
ers were present minimally in the normal valves. Conclusions: These findings strongly
suggest that rheumatic valve calcification results from ongoing osteoblast bone formation
and neoangiogenesis. Neither of those cellular processes are passive or random; both
are active and regulated by multiple inflammatory mediators which are important in bone
formation.
1107-136 Progression of Aortic Valve Calcification Measured by 
Electron Beam Computed Tomography: A Population-
Based Study
David Messika-Zeitoun, Lawrence F. Bielak, Patricia A. Peyser, Patrick F. Sheedy, II, 
Jerome Breen, Marie-Christine Aubry, Maurice Enriquez-Sarano, Mayo Clinic, Rochester, 
MN, University of Michigan, Ann Arbor, MI
Background: Calcification of the aortic valve has been recently linked to poor outcome.
However, prevalence, progression and association to cardiovascular risk factors and sub-
clinical atherosclerosis are unknown
Methods: Between 1996 and 1999, 262 research participants >60 years (68±5 years,
43% male) enrolled in a prospective population-based study underwent Electron Beam
Computed Tomography (ECBT) for assessment of aortic valve (AVC) and coronary artery
(CAC) calcifications
Results: Prevalence: Prevalence of AVC was 30% and increased with age (<65 years:
15%; 65-70 years: 35% and >70 years: 42%; p<0.01) Association to cardiovascular risk
factors and CAC: History of diabetes and hypertension, serum glucose and body mass
index were significantly associated with AVC (all p<0.05). Patients with AVC had higher
CAC (441±802 vs. 265±566, p<0.01) independent of age Progression: After a mean fol-
low-up of 3.8±0.9 years, AVC increased (baseline: 54±173, follow-up: 94±271, p<0.01)
and more so in patients with than without baseline AVC (+37±53 vs. +1±4 /year, p<0.01).
Overall, independent predictors of AVC progression were baseline AVC (p<0.01) and
LDL-C (p<0.01). Compared to the 173 AVC-free participants (baseline and follow-up),
total and LDL-C and CAC progression (adjusted for baseline score) were higher in the 19
with AVC-acquisition at follow-up (respectively 235±39 vs. 209±33 mg/dL; 141±31 vs.
121±27 mg/dL; +78±87 vs. +28±47 /year, all p<0.01) but not in the 70 with established
AVC at baseline (respectively 205±35; 120±31; +53±58; all p>0.40). LDL-C was the only
independent determinant of acquisition of AVC and baseline AVC of progression of AVC
in the AVC established group
Conclusion: In the population, AVC 1) is frequent and increases with age, 2) is associ-
ated with atherosclerotic risk factors, 3) is a marker of more severe coronary artery dis-
ease a potential mechanism for poor outcome 4) appears de novo in a context of
progressive atherosclerosis 5) whereas established AVC progresses independently of
atherosclerotic risk factors and faster with increasing AVC loads. These data underscore
the importance of AVC measurement by EBCT and of evaluating strategies to slow the
disease progression
1107-137 Influence of C-Reactive Protein on Matrix Remodeling in 
Calcific Aortic Stenosis
Jens J. Kaden, Carl-Erik Dempfle, Hanh-Thai Tran, Siegfried Lang, Rainer Grobholz, 
Siegfried Hagl, Martina Brueckmann, Karl K. Haase, Martin Borggrefe, University 
Hospital Mannheim, Mannheim, Germany, University Hospital Heidelberg, Heidelberg, 
Germany
Background: Calcific aortic stenosis (AS) is based on an inflammatory process leading
to marked remodeling of the extracellular matrix. We have shown that matrix metallopro-
teinase (MMP)-1 contributes to this process. Recent studies showed that serum levels of
the inflammatory mediator C-reactive protein (CRP) are elevated in patients with calcific
AS, however, its the role during the pathogenesis of calcific aortic stenosis is unknown.
Methods: Human tricuspid aortic valves with calcific AS (n=11) were obtained at valve
replacement, sclerotic valves without stenosis (n=5) and normal valves (n=4) at autopsy.
CRP immunostaining was performed using monoclonal antibodies, and staining intensi-
ties were assessed by semiquantitative scoring. Human aortic valve myofibroblasts were
cultured with and without addition of CRP. MMP-1 expression was assessed by Western
blotting.
Results: No staining for CRP was detectable in normal valves. Sclerotic valves showed
moderate staining, stenotic valves intense staining (p<0.05 by Kruskal-Wallis test). Stim-
ulation of human aortic valve myofibroblasts with CRP lead to a time-dependent increase
in MMP-1 as compared to unstimulated controls.
Conclusion: CRP staining is absent in normal valves, present in sclerotic valves and
strong in stenotic valves. Stimulation of cultured human aortic valve myofibroblasts with
CRP leads to increased expression of MMP-1. These results suggest a pathogenetic
influence of CRP on tissue remodeling during calcific AS, further supporting the concept
of calcific AS as an inflammatory disorder.
1107-138 Statin Therapy Does Not Affect Bioprosthetic Valve 
Degeneration
Raphael Rosenhek, Florian Rader, Maria Heger, Harald Gabriel, Thomas Binder, Gerald 
Maurer, Helmut Baumgartner, University of Vienna, Vienna, Austria
Background: Several recent studies have suggested that statins reduce the hemody-
namic progression of calcific aortic stenosis. Similarly, a slower rate of bioprosthetic valve
degeneration has recently been reported for statin-treated patients. However, the differ-
ences in underlying pathophysiolgical mechanisms of these two disorders question such
positive statin effects. Thus, further retrospective analyses are required before prospec-
tive randomized trials can be justified.
Methods: 202 pts (71±11 years, 118 female) with bioprosthetic aortic valves, normal left
ventricular function and no other significant valvular lesion who were examined between
2000 and 2002 and who had two echocardiograms separated by at least 6 months were
studied (mean interval 28±17 months). Of these, 84 pts (42%) were on statin therapy.
The change in peak transprosthetic velocity (TP-Vel) during follow-up was assessed.
No Recurrent MR Recurrent MR P-value
Data Availability (N) 298 63
Days of Follow-up 262±546 190±384 NS
Age (years) 66±9 67±8 NS
Male/Female 193/105 39/24 NS
EF (%) 33±11 32±10 NS
LAD (cm) 4.56±0.8 4.89±0.6 0.01
LVDD (cm) 5.77±0.86 6.06±0.71 0.04
LVSD (cm) 4.09±1.03 4.85±0.74 0.03
Pre-Op MR (0~4+) 2.67±0.84 3.15±0.86 <0.0001
